![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 1-Apr-2013[ | E-mail |
Share ] Contact: Heather Buschman
hbuschman@sanfordburnham.org
858-795-5343
Sanford-Burnham Medical Research Institute
Sanford-Burnham researchers discover that, in both mice and humans, the enzyme PKCzeta acts as a tumor suppressor by keeping the pro-tumor c-Myc gene in check
LA JOLLA, Calif., April 1, 2013 Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have identified how an enzyme called PKC? suppresses prostate tumor formation. The finding, which also describes a molecular chain of events that controls cell growth and metastasis, could lead to novel ways to control disease progression.
Working in close collaboration, the labs of Maria T. Diaz-Meco, Ph.D., and Jorge Moscat, Ph.D., found that PKC? controls the activation of a pro-tumor gene called c-Myc. Normally, PKC?'s alteration keeps c-Myc in check. But PKC? levels are low in prostate and other cancers, leaving c-Myc free to enhance cell growth and metastasis. This study, published April 1 in the Proceedings of the National Academy of Sciences, suggests that restoring PKC? could provide a new approach to treating prostate cancer.
How PKC? acts as a prostate tumor suppressor
Previous studies suggested that PKC? might act as a tumor suppressorbut that wasn't clear in the case of prostate cancer. In their study, the team learned of PKC?'s role after genetically engineering mice so they lacked the enzyme altogether.
"In this study, we assessed the role of PKC? in prostate cancer, and for the first time we used a knockout mouse for PKC? to demonstrate that it's actually a tumor suppressor," Diaz-Meco said. "But, I think the major advance in this paper is that we found out how PKC? is a tumor suppressor in prostate cancer."
In their study, the researchers found that PKC? suppresses tumors in cooperation with a gene called PTEN. PTEN has been long known to act as a tumor suppressor, and it's also well-established that its mutated form is common in prostate cancer.
But the loss of normal PTEN function alone doesn't lead to aggressive prostate cancer. According to this study, the loss of PKC? and the resulting over-active c-Myc are also needed for aggressive prostate cancer to develop.
Potential approaches toward attacking prostate cancer may in the future involve activating PKC? through gene therapy, or dealing with its inaction downstreamperhaps by finding another way to inhibit c-Myc in the absence of PKC?.
###
This research was funded by the U.S. National Institutes of Health (National Cancer Institute grants R01CA134530, R01CA132847, and 5P30CA030199-31; National Institute of Allergy and Infectious Diseases grant R01AI072581; National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK088107) and the Department of Defense (grant DoD-PC080441).
The study was co-authored by Ji Young Kim, Sanford-Burnham; Tania Valencia, Sanford-Burnham; Shadi Abu-Baker, University of Cincinnati Medical College; Juan F. Linares, Sanford-Burnham; Sang Jun Lee, Sanford-Burnham; Tomoko Yajima, Sanford-Burnham; Jing Chen, University of Cincinnati Medical College; Alexey Eroshkin, Sanford-Burnham; Elias A. Castilla, University of Cincinnati Medical College; Laurence M. Brill, Sanford-Burnham; Mario Medvedovic, University of Cincinnati Medical College; Michael Leitges, University of Oslo; Jorge Moscat, Sanford-Burnham; and Maria T. Diaz-Meco, Sanford-Burnham.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), California and Orlando (Lake Nona), Florida. For more information, visit us at sanfordburnham.org.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 1-Apr-2013[ | E-mail |
Share ] Contact: Heather Buschman
hbuschman@sanfordburnham.org
858-795-5343
Sanford-Burnham Medical Research Institute
Sanford-Burnham researchers discover that, in both mice and humans, the enzyme PKCzeta acts as a tumor suppressor by keeping the pro-tumor c-Myc gene in check
LA JOLLA, Calif., April 1, 2013 Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have identified how an enzyme called PKC? suppresses prostate tumor formation. The finding, which also describes a molecular chain of events that controls cell growth and metastasis, could lead to novel ways to control disease progression.
Working in close collaboration, the labs of Maria T. Diaz-Meco, Ph.D., and Jorge Moscat, Ph.D., found that PKC? controls the activation of a pro-tumor gene called c-Myc. Normally, PKC?'s alteration keeps c-Myc in check. But PKC? levels are low in prostate and other cancers, leaving c-Myc free to enhance cell growth and metastasis. This study, published April 1 in the Proceedings of the National Academy of Sciences, suggests that restoring PKC? could provide a new approach to treating prostate cancer.
How PKC? acts as a prostate tumor suppressor
Previous studies suggested that PKC? might act as a tumor suppressorbut that wasn't clear in the case of prostate cancer. In their study, the team learned of PKC?'s role after genetically engineering mice so they lacked the enzyme altogether.
"In this study, we assessed the role of PKC? in prostate cancer, and for the first time we used a knockout mouse for PKC? to demonstrate that it's actually a tumor suppressor," Diaz-Meco said. "But, I think the major advance in this paper is that we found out how PKC? is a tumor suppressor in prostate cancer."
In their study, the researchers found that PKC? suppresses tumors in cooperation with a gene called PTEN. PTEN has been long known to act as a tumor suppressor, and it's also well-established that its mutated form is common in prostate cancer.
But the loss of normal PTEN function alone doesn't lead to aggressive prostate cancer. According to this study, the loss of PKC? and the resulting over-active c-Myc are also needed for aggressive prostate cancer to develop.
Potential approaches toward attacking prostate cancer may in the future involve activating PKC? through gene therapy, or dealing with its inaction downstreamperhaps by finding another way to inhibit c-Myc in the absence of PKC?.
###
This research was funded by the U.S. National Institutes of Health (National Cancer Institute grants R01CA134530, R01CA132847, and 5P30CA030199-31; National Institute of Allergy and Infectious Diseases grant R01AI072581; National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK088107) and the Department of Defense (grant DoD-PC080441).
The study was co-authored by Ji Young Kim, Sanford-Burnham; Tania Valencia, Sanford-Burnham; Shadi Abu-Baker, University of Cincinnati Medical College; Juan F. Linares, Sanford-Burnham; Sang Jun Lee, Sanford-Burnham; Tomoko Yajima, Sanford-Burnham; Jing Chen, University of Cincinnati Medical College; Alexey Eroshkin, Sanford-Burnham; Elias A. Castilla, University of Cincinnati Medical College; Laurence M. Brill, Sanford-Burnham; Mario Medvedovic, University of Cincinnati Medical College; Michael Leitges, University of Oslo; Jorge Moscat, Sanford-Burnham; and Maria T. Diaz-Meco, Sanford-Burnham.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), California and Orlando (Lake Nona), Florida. For more information, visit us at sanfordburnham.org.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-04/smri-nit040113.php
meek sturgis sturgis whitney houston laid to rest daytona bike week mary kay ash tiny houses
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.